Jun 18 |
Aptose Announces Results from Annual and Special Meeting of Shareholders
|
Jun 14 |
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
|
Jun 13 |
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
|
Jun 3 |
Aptose Closes U$4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Jun 3 |
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
May 31 |
Aptose Biosciences Down 14% In US Premarket As Plans to Raise Near $4.4 Million Via Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
May 31 |
Aptose Biosciences looks to raise $4.43M in a direct offering
|
May 31 |
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-MarketĀ Under Nasdaq Rules
|
May 15 |
Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript
|
May 14 |
Aptose Biosciences GAAP EPS of -$0.73 beats by $0.09
|